Answers are grounded in this paper and cite their sources.
We report a patient on maintenance hemodialysis who presented with systemic oxalosis manifesting as shrunken hyperdense kidneys, diffusely increased bone density, soft-tissue calcifications, and refractory hypoalbuminemia. Whole-exome sequencing (WES) identified only one pathogenic allele, a heterozygous frameshift duplication in AGXT , c.823_824dupAG (p.Ser275Argfs*38). Subsequent whole-genome sequencing (WGS) revealed a previously unreported deep intronic variant c.525-158C>T in AGXT intron 4, classified as likely pathogenic according to the ACMG/AMP guidelines. This compound heterozygosity, together with the characteristic clinical and histological features, supports a clinical diagnosis of primary hyperoxaluria type 1 (PH1). According to the patient’s own report, numbness and pain in the extremities were substantially relieved following two successive sodium thiosulfate (STS) administration regimens, with concomitant high-dose pyridoxine and intensified high-flux hemodialysis. This case highlights the diagnostic delay of PH1 in adults with unexplained kidney failure and the ascertainment gap of exome-based testing for deep intronic splice-altering variants, and supports pursuing WGS when clinical suspicion persists despite inconclusive WES. In addition, the role of STS in the management of PH1 may merit further investigation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: